Loss of heterozygosity at chromosome 11 in breast cancer: Association of prognostic factors with genetic alterations

We examined DNA from 116 female and four male breast cancer patients for loss of heterozygosity (LOH). DNA was analysed by polymerase chain reaction using ten microsatellite markers on chromosome 11. Three distinct regions of LOH were identified: 11p15.5, 11q13 and 11q22-qter with a LOH frequency of...

Full description

Bibliographic Details
Main Authors: Sigurður Ingvarsson 1956-, Júlíus Guðmundsson 1968-, Rósa Björk Barkardóttir 1958-, Guðný Eiríksdóttir 1950-, Aðalgeir Arason 1957-, Valgarður Egilsson 1940-, Trausti Baldursson 1956-
Other Authors: Háskóli Íslands
Format: Article in Journal/Newspaper
Language:English
Published: 1995
Subjects:
Online Access:http://hdl.handle.net/1946/20708
Description
Summary:We examined DNA from 116 female and four male breast cancer patients for loss of heterozygosity (LOH). DNA was analysed by polymerase chain reaction using ten microsatellite markers on chromosome 11. Three distinct regions of LOH were identified: 11p15.5, 11q13 and 11q22-qter with a LOH frequency of 19, 23 and 37-43% respectively. The marker D11S969 showing the highest frequency of LOH (43%) is located at the 11q24.1-q25 region. No previous molecular genetic studies have shown frequent LOH at the region telomeric to q23 on chromosome 11. Southern analysis revealed that LOH at 11q13 was due to amplification, whereas LOH at 11q22-qter was due to deletion. LOH at 11p15.5 was associated with paucity of hormone receptor proteins, high S-phase and positive node status. An association was found between LOH at 11q13 and positive node status. LOH at the 11q22-qter region correlated with a high S-phase fraction. A significant association was found between LOH at 11p15 and chromosome regions 17q21 (the BRCA1 region) and 3p. Nordic Council of Ministers, University of Iceland Graduate Research Fund, the Nordic Cancer Union, the Icelandic Cancer Society, the Memorial Fund of Bergthora Magnusdottir and Jakob B Bjarnason, the Science Fund of Iceland and the Science Fund of the University Hospital of Iceland.